Wesley Yin, PhD; Anirban Basu, PhD; James X. Zhang, PhD; Atonu Rabbani, PhD; David O. Meltzer, MD, PhD; G. Caleb Alexander, MD, MS
Grant Support: Dr. Zhang was supported in part by a grant from Merck & Co. Dr. Meltzer is supported by the Centers for Disease Control and Prevention Chicago Center of Excellence in Health Promotion Economics and the Merck Foundation through the University of Chicago Program for Pharmaceutical Policy Research. Dr. Alexander is supported by career development awards from the Agency for Healthcare Research and Quality (K08 HS15699-01A1) and the Robert Wood Johnson Physician Faculty Scholars Program.
Potential Financial Conflicts of Interest:Consultancies: A. Basu (Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, FasterCures, Best Practice), D.O. Meltzer (Pfizer, Merck & Co., Eli Lilly, AstraZeneca, TAP Pharmaceuticals), G.C. Alexander (AstraZeneca). Grants received: A. Basu (Pfizer), J.X. Zhang (Merck & Co.), D.O. Meltzer (Pfizer, Merck & Co., Eli Lilly, AstraZeneca, TAP Pharmaceuticals), G.C. Alexander (Merck & Co., Pfizer). Other: D.O. Meltzer (Medicare Trustees Technical Advisory Panel).
Requests for Single Reprints: G. Caleb Alexander, MD, MS, University of Chicago, 5841 South Maryland, MC 2007, Chicago, IL 60637; e-mail, email@example.com.
Current Author Addresses: Dr. Yin: Harvard University, 1730 Cambridge Street, s409, Cambridge, MA 02138.
Drs. Basu, Rabbani, Meltzer, and Alexander: University of Chicago, 5841 South Maryland, MC 2007, Chicago, IL 60637
Dr. Zhang: Department of Pharmacy, Virginia Commonwealth University, Smith Building, Room 434, 410 North 12th Street, Richmond, VA 23298-0533.
Author Contributions: Conception and design: W. Yin, A. Basu, J.X. Zhang, G.C. Alexander.
Analysis and interpretation of the data: W. Yin, A. Basu, J.X. Zhang, G.C. Alexander.
Drafting of the article: W. Yin, A. Basu, G.C. Alexander.
Critical revision of the article for important intellectual content: W. Yin, A. Basu, J.X. Zhang, A. Rabbani, G.C. Alexander.
Final approval of the article: W. Yin, A. Basu, J.X. Zhang, G.C. Alexander.
Provision of study materials or patients: W. Yin.
Statistical expertise: W. Yin, A. Basu, J.X. Zhang, A. Rabbani.
Obtaining of funding: W. Yin, G.C. Alexander.
Administrative, technical, or logistic support: W. Yin, A. Basu.
Collection and assembly of data: W. Yin, A. Rabbani, G.C. Alexander.
Information about the effect of the Medicare Part D Prescription Drug Benefit on drug utilization and expenditures is limited.
To estimate changes in prescription utilization and out-of-pocket expenditures attributable to Part D among a sample of persons eligible for the benefit.
Generalized estimating equations were used to estimate changes in expenditures and utilization among beneficiaries. A control group was included to control for secular trends unrelated to the Part D benefit.
National pharmacy chain representing approximately 15% of all U.S. retail pharmacy sales.
Persons age 66 to 79 years (those eligible for Part D) and a control group of persons age 60 to 63 years (those ineligible for Part D). The final sample represented approximately 5.1 million unique beneficiaries and 1.8 million unique control individuals.
Prescription utilization (measured in pill-days) and out-of-pocket expenditures, as determined from pharmacy claims from September 2004 to April 2007.
During the penalty-free Part D enrollment period (January 2006 to May 2006), average monthly drug utilization increased by 1.1% (95% CI, 0.5% to 1.7%; P < 0.001) and out-of-pocket expenditures decreased by 8.8% (CI, 6.6% to 11.0%; P < 0.001). After enrollment stabilized (June 2006 to April 2007), average monthly drug utilization increased by 5.9% (CI, 5.1% to 6.7%; P < 0.001) and out-of-pocket expenditures decreased by 13.1% (CI, 9.6% to 16.6%; P = 0.003). Compared with eligible nonenrollees, enrollees had higher out-of-pocket expenditures and utilization at baseline but experienced significantly larger decreases in expenditures and increases in utilization after enrollment.
Analyses were limited to claims within 1 pharmacy chain. The effect of the “doughnut hole” and the effect of changes on clinical outcomes were not evaluated.
The Medicare Part D prescription benefit resulted in modest increases in average drug utilization and decreases in average out-of-pocket expenditures among Part D beneficiaries. Further research is needed to examine patterns among other beneficiaries and to evaluate the effect of these changes on health outcomes.
In 2006, Medicare inaugurated a drug benefit for older adults.
Using data from a random sample of pharmacy customers who were beneficiaries of the program after the enrollment deadline, the authors estimate that the drug benefit saved people about $9 a month and gave them an extra 14 days of pills, on average.
The authors did not examine effects of the doughnut hole and did not look at specific drugs or drug classes.
The Medicare drug benefit has led to modest decreases in expense and increases in drug use for older adults.
Full specification of the generalized estimating equation model.
Table 1. Sample Characteristics*
Appendix Table 1. Comparison of Participant Characteristics with Those of a Nationally Representative Sample Derived from the Behavioral Risk Factor Surveillance Survey*
Trends in out-of-pocket prescription expenditures.
Top. Trends in average monthly out-of-pocket costs. Bottom. Trend in factual out-of-pocket costs versus counterfactual costs associated with no implementation of Part D. GEE = generalized estimating equation.
Trends in prescription drug utilization.
Top. Monthly pill-days of drug utilization. Bottom. Trend in factual utilization versus counterfactual utilization associated with no implementation of Part D. GEE = generalized estimating equation.
Appendix Table 2. Coefficients from Generalized Estimating Equation Models*
Table 2. Effect of Medicare Part D on Out-of-Pocket Prescription Expenditures and Utilization
Trends in out-of-pocket expenditures, by Part D enrollment.
Top. Trends in average monthly out-of-pocket costs. Bottom. Trends in factual out-of-pocket costs versus counterfactual costs associated with no implementation of Part D. GEE = generalized estimating equation.
Trends in prescription drug utilization, by Part D enrollment.
Top. Monthly pill-days of drug utilization. Bottom. Trends in factual out-of-pocket costs versus counterfactual costs associated with no implementation of Part D. GEE = generalized estimating equation.
Table 3. Effect of Medicare Part D on Out-of-Pocket Prescription Expenditures and Utilization, by Part D Enrollment*
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Yin W, Basu A, Zhang JX, Rabbani A, Meltzer DO, Alexander GC. The Effect of the Medicare Part D Prescription Benefit on Drug Utilization and Expenditures. Ann Intern Med. ;148:169–177. doi: 10.7326/0003-4819-148-3-200802050-00200
Download citation file:
Published: Ann Intern Med. 2008;148(3):169-177.
Healthcare Delivery and Policy.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use